October 2019 - Clinical trial profile - locations, conditions, companies -

Clinical Trials for Daytrana

Subscribe to access the full database, or request a copy of the full page.
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00434213	Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA	Completed	Noven Therapeutics	Phase 4	2007-01-01	This is a study designed to characterize the dermal response of DAYTRANA. Subjects will visit the study site over a period of approximately 14 weeks.
NCT00499863	Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD	Completed	Noven Therapeutics	Phase 3	2007-07-01	To assess the efficacy and safety of efficacy of MTS compared to placebo
NCT00501293	Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD	Completed	Noven Therapeutics	Phase 3	2007-08-01	To evaluate the long-term, safety of Methylphenidate Transdermal System (MTS) in aged 13-17 years diagnosed withADHD
NCT00506285	Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD	Completed	Shire	Phase 3	2007-06-01	This study will look at the effectiveness of Methylphenidate Transdermal System (MTS) in treating adult ADHD. MTS has received FDA approval for childhood ADHD but this is the first trial for adult ADHD. Subjects will experience two screening visits and one baseline visit. Those who meet admission criteria will enter the double-blind phase. This will involve two 4-week treatment periods one of which will involve the use of MTS and the other a placebo patch. Subjects who complete the double-blind phase will be allowed to enter a 180-day, open-label MTS phase designed to assess long-term effects.
NCT00506285	Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD	Completed	University of Utah	Phase 3	2007-06-01	This study will look at the effectiveness of Methylphenidate Transdermal System (MTS) in treating adult ADHD. MTS has received FDA approval for childhood ADHD but this is the first trial for adult ADHD. Subjects will experience two screening visits and one baseline visit. Those who meet admission criteria will enter the double-blind phase. This will involve two 4-week treatment periods one of which will involve the use of MTS and the other a placebo patch. Subjects who complete the double-blind phase will be allowed to enter a 180-day, open-label MTS phase designed to assess long-term effects.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary